Open access · CC-BY
via OpenAlex
NAD+ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension
Yumin Qiu, Shiyue Xu, Xi Chen, Xing Wu, Zhe Zhou, Jianning Zhang, Qiang Tu, Bing Dong, Zhefu Liu, Jiang He, Xiaoyu Zhang, Shuangshuang Liu, Shee‐Uan Chen, Hui Huang, Wenhao Xia
Signal Transduction and Targeted Therapy · 2023 · ▲ 62 citations
Abstract
Abstract Hypertension is characterized by endothelial dysfunction and arterial stiffness, which contribute to the pathogenesis of atherosclerotic cardiovascular diseases. Nicotinamide adenine dinucleotide (NAD + ) is an indispensable cofactor in all living cells that is involved in fundamental biological processes. However, in hypertensive patients, alterations in NAD + levels and their relation with blood pressure (BP) elevation and vascular damage have not yet been studied. Here we reported that hypertensive patients exhibited lower NAD + levels, as detected by high-performance liquid chromatography-mass spectrometry (HPLC-MS), in both peripheral blood mononuclear cells (PBMCs) and aortas, which was parallel to vascular dysfunction. NAD + boosting therapy with nicotinamide mononucleotide (NMN) supplement reduced BP and ameliorated vascular dysfunction in hypertensive patients (NCT04903210) and AngII-induced hypertensive mice. Upregulation of CD38 in endothelial cells led to endothelial NAD + exhaustion by reducing NMN bioavailability. Pro-inflammatory macrophages infiltration and increase in IL-1β generation derived from pro-inflammatory macrophages resulted in higher CD38 expression by activating JAK1-STAT1 signaling pathway. CD38 KO, CD38 inhibitors treatment, or adeno-associated virus (AAV)-mediated endothelial CD38 knockdown lowered BP and improved vascular dysfunction in AngII-induced hypertensive mice. The present study demonstrated for the first time that endothelial CD38 activation and subsequently accelerated NAD + degradation due to enhanced macrophage-derived IL-1β production was responsible for BP elevation and vascular damage in hypertension. NAD + boosting therapy can be used as a novel therapeutic strategy for the management of hypertensive patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41392-023-01577-3
- Canonical
- link ↗
- Fetched
- 2026-09-11 MST
Cite this
APA
Qiu, Y., Xu, S., Chen, X., Wu, X., Zhou, Z., Zhang, J., Tu, Q., Dong, B., Liu, Z., He, J., Zhang, X., Liu, S., Chen, S., Huang, H., Xia, W., & Tao, J. (2023). NAD+ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension. <em>Signal Transduction and Targeted Therapy</em>. https://doi.org/10.1038/s41392-023-01577-3
Vancouver
Qiu Y, Xu S, Chen X, Wu X, Zhou Z, Zhang J, et al. NAD+ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01577-3.
BibTeX
@article{yumin2023NADexh,
title = {NAD+ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension},
author = {Yumin Qiu and Shiyue Xu and Xi Chen and Xing Wu and Zhe Zhou and Jianning Zhang and Qiang Tu and Bing Dong and Zhefu Liu and Jiang He and Xiaoyu Zhang and Shuangshuang Liu and Shee‐Uan Chen and Hui Huang and Wenhao Xia and Jun Tao},
journal = {Signal Transduction and Targeted Therapy},
year = {2023},
doi = {10.1038/s41392-023-01577-3},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Elsevier eBooks 2023
Citation only
Pharmacology of NAD+boosters
Biochemical and Biophysical Research Communications 2019
Open access · CC-BY
The NADase CD38 is induced by factors secreted from senescent cells providing a potential link between senescence and age-related cellular NAD+ decline
American Journal of Clinical Nutrition 2012
Open access · OA
Higher anthocyanin intake is associated with lower arterial stiffness and central blood pressure in women
Clinical Hypertension 2023
Open access · CC-BY
Arterial stiffness and hypertension
Frontiers in Cardiovascular Medicine 2020
Open access · CC-BY
Arterial Stiffness and Hypertension in the Elderly
Likarska sprava 2017
Open access · CC-BY